Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy
Launched by AUROLAB · Jul 21, 2006
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
Proliferative Diabetic Retinopathy is ocular pathology in poor glycaemic controlled Diabetic patient Characterized by micro-vascular pathology with capillary closure in the retina leading to hypoxia of tissue there by formation of immature vessels to provide better oxygenation of retinal tissue.
In this randomized double blinded study a convenient sample size of 24 eyes assigned to compare indigenously developed green laser with already available green laser.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients more than 18 years of age
- • Eyes with proliferative diabetic retinopathy requiring laser photocoagulation
- Exclusion Criteria:
- • Eyes with media opacities not allowing proper fundus photography or adequate laser photocoagulation
- • Patients requiring more than two sessions of laser photocoagulation
- • Patients who had undergone previous laser photocoagulation
- • Patients who had undergone any previous vitreo-retinal surgery
About Aurolab
Aurolab is a leading global organization dedicated to advancing eye care through the development and manufacturing of innovative medical devices and pharmaceuticals. Based in India, Aurolab specializes in producing high-quality ophthalmic products, including intraocular lenses and surgical instruments, aimed at improving patient outcomes and accessibility to eye care solutions. Committed to research and development, Aurolab actively sponsors clinical trials to evaluate the safety and efficacy of its products, ensuring compliance with international standards and contributing to the global fight against blindness. Through collaboration with healthcare professionals and institutions, Aurolab strives to enhance vision health and promote sustainable eye care practices worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madurai, Tamil Nadu, India
Patients applied
Trial Officials
Chandra Mohan, MS
Principal Investigator
Arvind Eye Hospital, Madurai
Dhananjay Shukla, MS
Principal Investigator
Aravind Eye Hospital
Naresh Babu, MS, FNB
Principal Investigator
Aravind Eye Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials